Zhengye Biotechnology Holding (ZYBT) Receivables (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Receivables for 3 consecutive years, with $5.3 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Receivables fell 51.11% year-over-year to $5.3 million in Q4 2025; TTM through Dec 2025 was $5.3 million, a 51.11% decrease from a year earlier, with the FY2025 full-year figure at $8.4 million, down 21.93% from the prior year.
• Receivables was $5.3 million for Q4 2025 at Zhengye Biotechnology Holding, down from $7.4 million in the prior quarter.
• Over five years, Receivables peaked at $12.8 million in Q4 2023 and troughed at $5.3 million in Q4 2025.
• A 3-year average of $9.1 million and a median of $9.1 million in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables declined 15.96% in 2024 and sank 51.11% in 2025, its largest moves.
• Over 3 years, Receivables stood at $12.8 million in 2023, then fell by 15.96% to $10.7 million in 2024, then slumped by 51.11% to $5.3 million in 2025.
• The last three Receivables figures came in at $5.3 million (Q4 2025), $7.4 million (Q2 2025), and $10.7 million (Q4 2024), per Business Quant data.